A decade ago, there was a lot of excitement about INGAP (which stands for Islet Neogenesis Associated Protein), but for a variety of different reasons, much of that excitement disappeared to the point where many new patients or parents of children with type 1 diabetes really know little about this promising potential treatment, even though many diabetes veterans view all regeneration efforts -- including Denise Faustman's -- as having a number of similarities.



Back in March, I wrote… Continue

The Associated Press recently featured a story on my subject for today which began as follows: "When a state trooper pulls over a speeding motorist, the officer usually writes out a ticket on the spot."



However, when federal regulators catch a pharmaceutical company marketing prescription medications for an "unapproved" use, it typically takes the U.S. FatalFood and Drug Administration (FDA)… Continue

You'd think the U.S. FatalFood and Drug Administration (FDA) would be on the mend. After all, last December, The New York Times reported that the FDA is desperately short of money and poorly organized, which is putting people's lives at risk. A report entitled… Continue

First of all, a hat tip to Peter Rost, as the physician and former drug marketer for Pfizer turned whistle-blower and blogger featured this story on his blog late last week.



At issue is something Americans, and perhaps too often, patients with diabetes fail to consider, and that is when their doctor(s) recommend the latest and greatest new drug, insulin, device or other… Continue